Skip to main content
Journal cover image

Effect of serelaxin on mode of death in acute heart failure: results from the RELAX-AHF study.

Publication ,  Journal Article
Felker, GM; Teerlink, JR; Butler, J; Hernandez, AF; Miller, AB; Cotter, G; Davison, BA; Filippatos, G; Greenberg, BH; Ponikowski, P; Voors, AA ...
Published in: J Am Coll Cardiol
October 14, 2014

BACKGROUND: Little is known about mode of death after acute heart failure (AHF) hospitalization. In the RELAX-AHF (Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure) study, serelaxin, the recombinant form of human relaxin-2, reduced post-discharge mortality at 180 days in selected patients with AHF. OBJECTIVES: The goal of this study was to assess the effect of serelaxin on specific modes of death in patients with AHF. METHODS: The RELAX-AHF study randomized 1,161 patients with AHF to 48 h of therapy with intravenous serelaxin or placebo. Patients were followed for vital status through 180 days. A blinded clinical events committee reviewed all deaths and adjudicated a cause of death on the basis of pre-specified criteria. Cox proportional hazard models were used to assess the effect of serelaxin on each mode of death, on the basis of pre-specified groupings of mode of death. RESULTS: There were 107 deaths (9.3%): 37 (35%) due to HF, 25 (23%) due to sudden death, 15 (14%) due to other cardiovascular (CV) causes, 19 (18%) due to non-CV causes, and 11 (10%) classified as unknown. The treatment effect of serelaxin was most pronounced on other CV deaths (hazard ratio [HR]: 0.29; 95% CI: 0.12 to 0.73; p = 0.005) and sudden death (HR: 0.46; 95% CI: 0.20 to 1.07; p = 0.065). There was no apparent impact of serelaxin treatment on HF deaths or non-CV deaths. CONCLUSIONS: In the RELAX-AHF study, the effects of serelaxin on mortality were primarily driven by reduction in mortality from other CV causes and sudden death, without apparent impact on HF deaths. (Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure [RELAX-AHF]; NCT00520806).

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Am Coll Cardiol

DOI

EISSN

1558-3597

Publication Date

October 14, 2014

Volume

64

Issue

15

Start / End Page

1591 / 1598

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Survival Rate
  • Relaxin
  • Recombinant Proteins
  • Prospective Studies
  • Male
  • Injections, Intravenous
  • Humans
  • Heart Failure
  • Follow-Up Studies
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Felker, G. M., Teerlink, J. R., Butler, J., Hernandez, A. F., Miller, A. B., Cotter, G., … Metra, M. (2014). Effect of serelaxin on mode of death in acute heart failure: results from the RELAX-AHF study. J Am Coll Cardiol, 64(15), 1591–1598. https://doi.org/10.1016/j.jacc.2014.05.071
Felker, G Michael, John R. Teerlink, Javed Butler, Adrian F. Hernandez, Alan B. Miller, Gad Cotter, Beth A. Davison, et al. “Effect of serelaxin on mode of death in acute heart failure: results from the RELAX-AHF study.J Am Coll Cardiol 64, no. 15 (October 14, 2014): 1591–98. https://doi.org/10.1016/j.jacc.2014.05.071.
Felker GM, Teerlink JR, Butler J, Hernandez AF, Miller AB, Cotter G, et al. Effect of serelaxin on mode of death in acute heart failure: results from the RELAX-AHF study. J Am Coll Cardiol. 2014 Oct 14;64(15):1591–8.
Felker, G. Michael, et al. “Effect of serelaxin on mode of death in acute heart failure: results from the RELAX-AHF study.J Am Coll Cardiol, vol. 64, no. 15, Oct. 2014, pp. 1591–98. Pubmed, doi:10.1016/j.jacc.2014.05.071.
Felker GM, Teerlink JR, Butler J, Hernandez AF, Miller AB, Cotter G, Davison BA, Filippatos G, Greenberg BH, Ponikowski P, Voors AA, Hua TA, Severin TM, Unemori E, Metra M. Effect of serelaxin on mode of death in acute heart failure: results from the RELAX-AHF study. J Am Coll Cardiol. 2014 Oct 14;64(15):1591–1598.
Journal cover image

Published In

J Am Coll Cardiol

DOI

EISSN

1558-3597

Publication Date

October 14, 2014

Volume

64

Issue

15

Start / End Page

1591 / 1598

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Survival Rate
  • Relaxin
  • Recombinant Proteins
  • Prospective Studies
  • Male
  • Injections, Intravenous
  • Humans
  • Heart Failure
  • Follow-Up Studies